This report provides exclusive insights into the COVID-19 impact on the Histone Deacetylase Inhibitors Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Histone Deacetylase Inhibitors Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Histone Deacetylase Inhibitors Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by
Infinium Global Research on histone deacetylase inhibitors market provides
in-depth analysis of segments and sub-segments in the global as well as
regional histone deacetylase inhibitors market. The study also highlights the
impact of drivers, restraints, and macro indicators on the global and regional
histone deacetylase inhibitors market over the short term as well as long term.
The report is a comprehensive presentation of trends, forecast and dollar
values of global histone deacetylase inhibitors market. According to the
report, the global histone deacetylase inhibitors market is projected to grow
at a CAGR of 5.9% over the forecast period of 2019-2025.
Histone deacetylase inhibitors are chemical
compounds that inhibit deacetylases. Histone deacetylase inhibitors have
potential applications in prognosis, treatment, and diagnosis of cancer.
Mergers and acquisitions are the key strategies used by market players. In
2019, Shenzhen Chipscreen Biosciences Co. Ltd. had a strategic partnership with
Novogene. The partnership stimulates the efficiency and success rate of drug
development and promotes effective and more personalized treatment.
The rising prevalence of cancer globally is a
major factor leading to the growth of the histone deacetylase inhibitors
market. As per the World Health Organization, around 9.6 million deaths
occurred in 2018 due to cancer. The surge in demand for improved and effective
therapies to treat cancer and other diseases drives the growth of market.
Histone deacetylase (HDAC) enzyme removes the acetyl group from histone
proteins on DNA and makes the DNA less accessible to transcription factors. The
high affinity and specificity of the HDAC enzyme will augment the expansion of
the histone deacetylase inhibitors market. In addition, growing awareness about
cancer and the growing number of clinical trials for different oncological
applications stimulates the growth of histone deacetylase inhibitors market. On
the other side, uncertainty and reimbursement issues with respect to HDAC
inhibitors hinder the market growth. Moreover, the surge in investments in HDAC
manufacturing and growing research and development activities in HDACs creates
numerous opportunities for the growth of the histone deacetylase inhibitors
North America region is anticipated to hold a
premium share in the global histone deacetylase inhibitors market owing to the growing
number of research and development activities and rapid technological
advancement. Europe is expected to grow in the global histone deacetylase
inhibitors market with a significant CAGR over the forecast period. The rapid
adoption of advanced therapeutics and well-established healthcare infrastructure
in Europe led to the market’s growth. Asia-Pacific is has a significant growth
rate in the global histone deacetylase inhibitors market. The increasing
healthcare infrastructure and rise in the number of cancer patients in the
Asia-Pacific region drive the growth of histone deacetylase inhibitors market
in Asia-Pacific. The prevalence of cancer cases in Asia-Pacific is expected to
increase to 70% by 2030.
The report on global histone
deacetylase inhibitors market covers segments such as class, and applications.
On the basis of class, the sub-markets include class I HDACs, class II HDACs,
and class III HDACs. On the basis of applications, the sub-markets include
neurology, oncology, central nervous system disorders, and other diseases.
The report provides profiles of
the companies in the market such as Novartis International AG, Celgene
Corporation, AstraZeneca plc, Acetylon Pharmaceuticals, Inc., FORUM
Pharmaceuticals, Inc., Celleron Therapeutics Ltd., Merck & Co., Inc.,
Spectrum Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co. Ltd.,
Oncolys BioPharma Inc., and other companies.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the histone deacetylase inhibitors market. Moreover, the study
highlights current market trends and provides forecast from 2019-2025. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.